Hypothalamic-Pituitary-Adrenocortical Axis Changes in the Rat after Long-Term Treatment with the Reversible Monoamine Oxidase-A Inhibitor Moclobemide

1994 ◽  
Vol 60 (5) ◽  
pp. 509-519 ◽  
Author(s):  
Johannes M.H.M. Reul ◽  
Marta S. Labeur ◽  
Dimitri E. Grigoriadis ◽  
Errol B. De Souza ◽  
Florian Holsboer
1980 ◽  
Vol 19 (9) ◽  
pp. 877-881 ◽  
Author(s):  
Pauline Lerner ◽  
L.F. Major ◽  
P.S. Dendel ◽  
I.C. Campbell ◽  
D.L. Murphy

1998 ◽  
Vol 13 (4) ◽  
pp. 203-209 ◽  
Author(s):  
M Versiani ◽  
AE Nardi ◽  
I Figueira

SummaryOpen trials with tricyclics, classical monoamine oxidase inhibitors (MAOIs) or lithium in dysthymia yielded a response rate in 45% of subjects. A long-term treatment of dysthymia with 276 patients treated during 4 years with either moclobemide, tranylcypromine or a combination of amitryptiline plus chlordiazepoxide is described. After discontinuation there was a relapse rate of 89.1%. The controlled studies with tricyclics, MAOIs, reversible inhibitors of monoamine oxidase (RIMAs), specific serotonin reuptake inhibitor (SSRIs) or benzamides showed that drugs well-tolerated work better in dysthymia, due to the fact that the treatment must be long-term. Sertraline was studied vs placebo or imipramine in primary dysthymia. Moclobemide, imipramine and placebo were also studied in 315 patients. Mean doses were 650 mg/d of moclobemide and 203.2 mg/d of imipramine. Moclobemide and sertraline were both efficacious and well tolerated. In a long term treatment the clinician should assess the risk-benefit ratio. Dysthymic patients are very sensitive to unwanted effects and compliance is a serious issue.


2021 ◽  
Vol 22 (15) ◽  
pp. 8089
Author(s):  
Anna Tkachev ◽  
Elena Stekolshchikova ◽  
Daniil M. Bobrovskiy ◽  
Nickolay Anikanov ◽  
Polina Ogurtsova ◽  
...  

Fluoxetine is an antidepressant commonly prescribed not only to adults but also to children for the treatment of depression, obsessive-compulsive disorder, and neurodevelopmental disorders. The adverse effects of the long-term treatment reported in some patients, especially in younger individuals, call for a detailed investigation of molecular alterations induced by fluoxetine treatment. Two-year fluoxetine administration to juvenile macaques revealed effects on impulsivity, sleep, social interaction, and peripheral metabolites. Here, we built upon this work by assessing residual effects of fluoxetine administration on the expression of genes and abundance of lipids and polar metabolites in the prelimbic cortex of 10 treated and 11 control macaques representing two monoamine oxidase A (MAOA) genotypes. Analysis of 8871 mRNA transcripts, 3608 lipids, and 1829 polar metabolites revealed substantial alterations of the brain lipid content, including significant abundance changes of 106 lipid features, accompanied by subtle changes in gene expression. Lipid alterations in the drug-treated animals were most evident for polyunsaturated fatty acids (PUFAs). A decrease in PUFAs levels was observed in all quantified lipid classes excluding sphingolipids, which do not usually contain PUFAs, suggesting systemic changes in fatty acid metabolism. Furthermore, the residual effect of the drug on lipid abundances was more pronounced in macaques carrying the MAOA-L genotype, mirroring reported behavioral effects of the treatment. We speculate that a decrease in PUFAs may be associated with adverse effects in depressive patients and could potentially account for the variation in individual response to fluoxetine in young people.


Sign in / Sign up

Export Citation Format

Share Document